T he importance of the endothelium to cardiovascular health cannot be overstated. This cell layer is the front line for regulation of vascular tone, permeability, platelet stability, and angiogenesis, with its dysfunction touted as a harbinger of cardiovascular disease. [1] [2] [3] Turnover of the endothelium in adults is relatively low, but proliferation can be triggered by inflammation, matrix disruption, or ischemia. 4 Our appreciation of this cell lining is acutely apparent following percutaneous coronary intervention, where delayed reendothelialization can cause thrombosis and exacerbate restenosis. 5 An even greater challenge is the aging patient with eroding endothelial function. 6 Indeed, an essential goal of cardiovascular science is to better elucidate the mechanisms that govern endothelial health and renewal.
In this issue of Circulation Research, Margariti et al provide evidence for a relationship between ␤-catenin and histone deacetylase (HDAC)7 in human endothelial cells. 7 Firstly, they demonstrate that overexpression of HDAC7 results in decreased ␤-catenin nuclear translocation, downregulation of ␤-catenin target genes, decreased ␤-catenin activity, and an associated inhibition of endothelial cell proliferation. Conversely, HDAC7 knockdown caused ␤-catenin nuclear translocation, but surprisingly also caused downregulation of cell cycle genes and a decrease in proliferation. These findings led Margariti et al to discover that HDAC7 can bind directly to ␤-catenin in endothelial cells. Moreover, vascular endothelial growth factor (VEGF)-induced endothelial cell proliferation was shown to be associated with HDAC7 degradation, disruption of HDAC7-␤-catenin binding and ␤-catenin nuclear translocation ( Figure A) . This novel protein-protein interaction balances nuclear trafficking and cytoplasmic sequestration of ␤-catenin, as well as transcriptional activity of ␤-catenin and degradation of HDAC7 (Figure, B ). This intracellular trafficking impacts endothelial proliferation and sets the stage for novel feedback mechanisms in VEGF receptor signaling and VEGF transcription.
In vascular biology, ␤-catenin is known for its dual function as both a component of the cadherin-cytoskeleton complex maintaining adherens junctions, and as the end transcriptional effector in Wnt signaling. 8, 9 Developmentally, endothelial-restricted loss of ␤-catenin demonstrated altered vascular morphology, hyperpermeability, and hemorrhage, leading to embryonic lethality. 10 Though this phenotype was attributed to impaired adherens junctions rather than vasculogenesis, ␤-catenin does play a role in adult angiogenesis. Indeed, 2 distinct and significant roles for ␤-catenin have been delineated in the endothelium according to its spatial association. In quiescent cells, ␤-catenin is bound to cadherin at the plasma membrane, whereas in pathophysiological contexts involving proliferative or angiogenic phenotypes, ␤-catenin accumulates either in the nucleus or cytoplasm. 11 As a cytoplasmic protein, ␤-catenin is regulated by phosphorylation at the NЈ and C' termini. The former targets it to a degradation complex (adenomatosis polyposis coli/Axin/ glycogen synthase kinase-3-␤), whereas the latter promotes nuclear accumulation and activity as a transcriptional cofactor. 12 However, ␤-catenin posttranslational modifications may not be limited to phosphorylation, because others have demonstrated a capacity for acetylation by CREBP (cAMP response element-binding protein)/E1A binding protein p300. 13, 14 Many genes relevant to endothelial function can be regulated by ␤-catenin, including myc, cyclins D1/E2, and VEGF. 15, 16 Accumulation of active ␤-catenin in endothelial cells by Wnt/VEGF stimulation or exogenous ␤-catenin expression promotes proliferation/tube formation in vitro and angiogenesis in vivo. 8, [17] [18] [19] [20] Thrombin-induced hyperpermeability and matrix metalloproteinase-induced proliferation results in the redistribution of ␤-catenin from cadherins to cytoplasm and nucleus. 21 Increased cytoplasmic ␤-catenin has been documented in the endothelial cells of preexisting and newly formed vessels after myocardial infarction, implicating ␤-catenin in the inflammation and neovascularization of the ischemic heart. 22 Endothelial cells manage 2 separate ␤-catenin functions through subcellular compartmentalization. Indeed, ectopic expression of the cytoplasmic domain of vascular endothelial cadherin attenuates ␤-catenin-dependent proliferation. 11 Therapies targeting ␤-catenin in endothelial cells may be developed from understanding ␤-catenin function, binding partners and the spatial-temporal resolution of molecular signaling in relevant phenotypes.
The HDAC family is similarly regulated by subcellular localization. HDACs shuttle between the cytoplasm and nucleus in response to extracellular signals, a process linked to both post translational modification and protein-protein interactions. 23 Serine phosphorylated HDAC is released from DNA-binding partners to link with 14-3-3 subunits for
The opinions expressed in this editorial are not necessarily those of the editors or of the American Heart Association. nuclear export. 24 This complex is generally thought to be in an inhibitory state; unable to interact with other transcription factors (as a repressor) and sequestered from histones. Classically, this allows chromatin expansion and permissive transcriptional activity. 23 In particular, HDAC7 has a unique role in endothelial regulation. 23 Some of its functions parallel ␤-catenin, including vascular integrity and intercellular adherence. Developmentally, systemic and endotheliumrestricted loss of HDAC7 revealed vessel instability, rupture and hemorrhage. 25 In part, this was because of its association with MEF2C (MADS box transcription enhancer factor 2, polypeptide C [myocyte enhancer factor 2C]) and downstream effector matrix metalloproteinases. 23, 25 However, signaling by VEGF is also regulated through HDAC7 release of MEF2C to upregulate matrix metalloproteinase-1/10 in angiogenesis. 26 Noteworthy is how these contrasting roles of HDAC7 in development versus adult angiogenesis mirror those of ␤-catenin. Now, Margariti et al identify a novel mechanism of HDAC7-dependent repression of ␤-catenin that is functionally distinct from typical HDAC activity. Whereas acetylation of proteins may be as relevant to cell signaling as phosphorylation, ancillary acetylase-independent HDAC functions are an emerging concept. Many HDACs, even in the same family, have disproportionate acetylase activity; HDAC7 is one example of an inefficient histone deacetylase. 27 Indeed, compared to class I HDAC, several class IIa HDAC possess a histidine substitution that impairs acteyl-lysine activity. 28 Other reports have shown these HDACs maintain repressor activity even in the absence of their catalytic C-terminal domain. 29 Accordingly, the work by Margariti et al reveals a new HDAC relationship involving ␤-catenin which may transform notions of 14-3-3-bound HDACs as functionally idle. The inhibitory protein-protein interaction between HDAC7 and ␤-catenin appears cytoplasm-specific, spatially distinguishing HDAC7 actions as a transcriptional corepressor in the nucleus, and adding another (cytoplasmic) layer to the structural (plasma membrane) and transcriptional functions (nucleus) of ␤-catenin. As such, this report provides an interesting contribution to a growing body of knowledge of putative acetylaseindependent HDAC mechanisms.
However, the study also contains unaccounted discrepancies that raise interesting questions. Margariti et al indicate VEGF signaling promotes proliferation and nuclear trafficking of ␤-catenin via HDAC7 degradation, repressed HDAC7 transcription, and putative release of unsequestered cytoplasmic ␤-catenin from HDAC7. They show that VEGF-induced proliferation is neutralized by HDAC7 overexpression. Therefore, VEGF-induced HDAC7 degradation would be expected to produce the same effect on endothelial cell proliferation as HDAC7 knockdown. However, VEGFinduced HDAC7 degradation, initiated endothelial cell proliferation, whereas HDAC7 silencing slightly reduced proliferation and expression of relevant cell cycle genes (Figure,  A) . Moreover, the expected reciprocity between HDAC7 overexpression versus knockdown is not observed, as both appear to inhibit proliferation.
Assuming no irregularities with the knockdown, these unexpected results may be attributable to fundamental differences in the spatial and temporal properties of HDAC7 between the experiments (Figure, B) . The temporal resolution of the effect of VEGF on HDAC7 spans minutes, whereas HDAC7 knockdown produces a prolonged deficit. Therefore, whereas short-term HDAC7 inhibition results in immediate ␤-catenin-induced proliferation, a chronic absence of HDAC7 could produce an opposite effect. Indeed, a longterm study of HDAC7 silencing demonstrated impaired endothelial migration and tube formation, 30 in agreement with the sustained knockdown Margariti et al reveal in their article. Moreover, it will be of interest to further explore the role of HDACs in VEGF signaling, as the VEGF promoter has consensus binding sequences for ␤-catenin. 31 Because VEGF-dependent HDAC7 inhibition is temporary, recovery of cytoplasmic HDAC7 function may provide a negative feedback to VEGF signaling through ␤-catenin.
Margariti et al show that the ancillary function of ␤-catenin sequestration was lost with HDAC7 knockdown, but so presumably are all other HDAC7 actions. For example, if HDAC7 binds ␤-catenin in the nucleus, a full circle feedback regulatory mechanism has yet to be fully described (Figure,  B) . This then would allow HDAC7, in concert with ␤-catenin, to produce a coordinate amplification of endothelial cell proliferation. Such a putative mechanism could account for the curious findings of Margariti et al and deserves further investigation.
Overall, the novel discovery of HDAC7-␤-catenin interactions in endothelial cells provides a launching point for several possible avenues of inquiry. To determine whether or not this protein-protein interaction is specific to the endothelium, a comparative analysis among cardiovascular tissues such as cardiomyocytes and vascular smooth muscle cells is merited. Margariti et al have conducted elegant analyses using models of HDAC7 overexpression and silencing in vitro. Exploring this relationship in vivo, particularly in relevant disease models is also warranted. Given that both HDAC7 and ␤-catenin are critical regulators of the endothelium, the importance of this interaction to vascular permeability, vasodilation, and platelet stability and lengthier phenotypes such as angiogenesis, inflammation, and remodeling should be determined. Indeed, the HDAC7-␤-catenin interaction may prove to be of clinical importance. For instance, genetic or acquired deficiencies in HDAC7 activity could have clinical ramifications for patients undergoing percutaneous coronary intervention, because HDAC7 dysfunction may exacerbate restenosis. Conversely, HDAC7-␤-catenin binding presents a novel putative therapeutic target for
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